MARKET

AMGN

AMGN

Amgen Inc
NASDAQ
299.02
+6.51
+2.23%
After Hours: 299.00 -0.02 -0.01% 19:58 07/16 EDT
OPEN
292.51
PREV CLOSE
292.51
HIGH
299.34
LOW
292.33
VOLUME
1.88M
TURNOVER
--
52 WEEK HIGH
336.01
52 WEEK LOW
249.07
MARKET CAP
160.78B
P/E (TTM)
27.29
1D
5D
1M
3M
1Y
5Y
1D
Amgen’s Phase 3 Study on Etelcalcetide: A Potential Game-Changer for Pediatric Kidney Patients
TipRanks · 10h ago
J&J leads big pharma higher after earnings despite Trump’s latest tariff threat
Seeking Alpha · 11h ago
JNJ Begins Drug Sector Q2 Earnings With a Beat & Guidance Raise
NASDAQ · 12h ago
Trump Threatens Pharma Tariffs This Month. Why the Stocks Are Looking Healthy.
Barron‘s · 16h ago
Trump eyes drug, chip tariffs by month-end
Seeking Alpha · 20h ago
Amgen: Biosimilars And Rare Disease Pipeline Crucial To Overcome Patent Cliff Concerns
Seeking Alpha · 23h ago
Earnings Preview: What to Expect From Amgen’s Report
Barchart · 23h ago
Dow Analyst Moves: AMGN
NASDAQ · 1d ago
More
About AMGN
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.

Webull offers Amgen Inc stock information, including NASDAQ: AMGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AMGN stock methods without spending real money on the virtual paper trading platform.